BR112015023017A2 - combinação de dois antivirais para o tratamento de hepatite c - Google Patents

combinação de dois antivirais para o tratamento de hepatite c

Info

Publication number
BR112015023017A2
BR112015023017A2 BR112015023017A BR112015023017A BR112015023017A2 BR 112015023017 A2 BR112015023017 A2 BR 112015023017A2 BR 112015023017 A BR112015023017 A BR 112015023017A BR 112015023017 A BR112015023017 A BR 112015023017A BR 112015023017 A2 BR112015023017 A2 BR 112015023017A2
Authority
BR
Brazil
Prior art keywords
treatment
antivirals
hepatitis
combination
ribavirin
Prior art date
Application number
BR112015023017A
Other languages
English (en)
Other versions
BR112015023017B1 (pt
Inventor
L Campbell Andrew
M Bernstein Barry
Lin Chih-Wei
M Menon Rajeev
Dutta Sandeep
J Podsadecki Thomas
Wang Tianli
M Awni Walid
Liu Wei
Original Assignee
Abbvie Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Family has litigation
First worldwide family litigation filed litigation Critical https://patents.darts-ip.com/?family=50588882&utm_source=google_patent&utm_medium=platform_link&utm_campaign=public_patent_search&patent=BR112015023017(A2) "Global patent litigation dataset” by Darts-ip is licensed under a Creative Commons Attribution 4.0 International License.
Application filed by Abbvie Inc filed Critical Abbvie Inc
Publication of BR112015023017A2 publication Critical patent/BR112015023017A2/pt
Publication of BR112015023017B1 publication Critical patent/BR112015023017B1/pt

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/4985—Pyrazines or piperazines ortho- or peri-condensed with heterocyclic ring systems
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/44—Non condensed pyridines; Hydrogenated derivatives thereof
    • A61K31/445—Non condensed piperidines, e.g. piperocaine
    • A61K31/4523—Non condensed piperidines, e.g. piperocaine containing further heterocyclic ring systems
    • A61K31/454—Non condensed piperidines, e.g. piperocaine containing further heterocyclic ring systems containing a five-membered ring with nitrogen as a ring hetero atom, e.g. pimozide, domperidone
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/41—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with two or more ring hetero atoms, at least one of which being nitrogen, e.g. tetrazole
    • A61K31/4164—1,3-Diazoles
    • A61K31/4184—1,3-Diazoles condensed with carbocyclic rings, e.g. benzimidazoles
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/498—Pyrazines or piperazines ortho- and peri-condensed with carbocyclic ring systems, e.g. quinoxaline, phenazine
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/16—Drugs for disorders of the alimentary tract or the digestive system for liver or gallbladder disorders, e.g. hepatoprotective agents, cholagogues, litholytics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12—Antivirals
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12—Antivirals
    • A61P31/14—Antivirals for RNA viruses
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • Chemical & Material Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Animal Behavior & Ethology (AREA)
  • Epidemiology (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Organic Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Oncology (AREA)
  • Communicable Diseases (AREA)
  • Virology (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Molecular Biology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Enzymes And Modification Thereof (AREA)
  • Peptides Or Proteins (AREA)
  • Medicines Containing Material From Animals Or Micro-Organisms (AREA)
  • Micro-Organisms Or Cultivation Processes Thereof (AREA)

Abstract

resumo “combinação de dois antivirais para o tratamento de hepatite c” a presente invenção apresenta interferon e terapias livre de ribavirina, para o tratamento de hcv. de preferência, o tratamento é superior a uma menor duração do tratamento, tal como não mais do que 12 semanas. em um aspecto, o tratamento compreende a administração de, pelo menos, dois agentes antivirais de atuação direta sem interferon e ribavirina a um indivíduo com infecção por hcv, em que o tratamento tem a duração de 12 semanas, e o referido, pelo menos, dois agentes antivirais de atuação direta compreendem: (a) o composto 1 ou um seu sal farma-ceuticamente aceitável e (b) o composto 2 ou um sal farmaceuticamente aceitável do mesmo.
BR112015023017-2A 2013-03-14 2014-03-14 Uso de pelo menos dois agentes antivirais de ação direta (daas) para o tratamento de infecção pelo vírus da hepatite c BR112015023017B1 (pt)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US201361783376P 2013-03-14 2013-03-14
US61/783,376 2013-03-14
PCT/US2014/027423 WO2014152514A1 (en) 2013-03-14 2014-03-14 Combination of two antivirals for treating hepatitis c

Publications (2)

Publication Number Publication Date
BR112015023017A2 true BR112015023017A2 (pt) 2017-07-18
BR112015023017B1 BR112015023017B1 (pt) 2022-08-30

Family

ID=50588882

Family Applications (1)

Application Number Title Priority Date Filing Date
BR112015023017-2A BR112015023017B1 (pt) 2013-03-14 2014-03-14 Uso de pelo menos dois agentes antivirais de ação direta (daas) para o tratamento de infecção pelo vírus da hepatite c

Country Status (26)

Country Link
US (1) US20140275099A1 (pt)
EP (3) EP3213750B1 (pt)
JP (4) JP6441303B2 (pt)
KR (2) KR20210013344A (pt)
CN (2) CN108159393A (pt)
AU (2) AU2014239563B2 (pt)
BR (1) BR112015023017B1 (pt)
CA (1) CA2901810C (pt)
CY (2) CY1119025T1 (pt)
DK (2) DK2968301T3 (pt)
EA (2) EA033257B1 (pt)
ES (2) ES2624980T3 (pt)
HK (2) HK1244668A1 (pt)
HR (2) HRP20171036T1 (pt)
HU (2) HUE033010T2 (pt)
IL (1) IL240419B (pt)
LT (2) LT2968301T (pt)
MX (2) MX362616B (pt)
NZ (2) NZ719137A (pt)
PL (2) PL2968301T3 (pt)
PT (2) PT2968301T (pt)
RS (2) RS56202B1 (pt)
SG (2) SG11201507364SA (pt)
SI (2) SI2968301T1 (pt)
TW (2) TWI686196B (pt)
WO (1) WO2014152514A1 (pt)

Families Citing this family (20)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US11484534B2 (en) 2013-03-14 2022-11-01 Abbvie Inc. Methods for treating HCV
US20160317603A9 (en) * 2013-03-14 2016-11-03 Abbvie Inc. Methods for Treating HCV
RS56202B1 (sr) 2013-03-14 2017-11-30 Abbvie Inc Kombinacija dva antivirotika za lečenje hepatitisa c
CA2916912A1 (en) * 2013-07-02 2015-01-08 Abbvie Inc. Methods for treating hcv
CA2925328A1 (en) * 2013-10-25 2015-04-30 Abbvie, Inc. Methods for treating hcv
WO2015095572A1 (en) * 2013-12-19 2015-06-25 Abbvie Inc. Methods for treating liver transplant recipients
CN110302361A (zh) * 2014-04-02 2019-10-08 艾伯维公司 治疗hcv的方法
JP7162425B2 (ja) * 2015-06-26 2022-10-28 アッヴィ・インコーポレイテッド Ｈｃｖを処置するための固体医薬組成物
US20160375017A1 (en) 2015-06-26 2016-12-29 Abbvie Inc. Solid Pharmaceutical Compositions for Treating HCV
AU2016291154B2 (en) * 2015-07-08 2021-10-21 Abbvie Inc. Methods for treating HCV
BR112018000982A2 (pt) * 2015-07-17 2018-09-11 Abbvie Inc composições farmacêuticas sólidas para tratar hcv
EA201892448A1 (ru) 2016-04-28 2019-06-28 Эмори Юниверсити Алкинсодержащие нуклеотидные и нуклеозидные терапевтические композиции и связанные с ними способы применения
JP2019529426A (ja) * 2016-09-23 2019-10-17 アッヴィ・インコーポレイテッド 用量調整
JP2018131439A (ja) * 2017-02-14 2018-08-23 アッヴィ・インコーポレイテッド Ｈｃｖを処置する方法
CA2981993A1 (en) * 2017-08-02 2019-02-02 Abbvie Inc. Methods for treating hcv
CN112351799A (zh) * 2018-04-10 2021-02-09 阿堤亚制药公司 具有硬化的hcv感染患者的治疗
EP3883569A1 (en) 2018-11-20 2021-09-29 Abbvie Inc. Methods for treating acute hcv
KR102077833B1 (ko) 2018-12-10 2020-02-14 류형준 기능성 식품조성물
CN111688355B (zh) 2019-03-15 2022-04-12 精工爱普生株式会社 液体吸收体、液体吸收器以及液体喷出装置
CA3136316A1 (en) * 2019-04-08 2020-10-15 Abbvie Inc. Solid pharmaceutical compositions for treating hcv

Family Cites Families (8)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US8937150B2 (en) * 2009-06-11 2015-01-20 Abbvie Inc. Anti-viral compounds
US9394279B2 (en) * 2009-06-11 2016-07-19 Abbvie Inc. Anti-viral compounds
SG188618A1 (en) * 2010-09-21 2013-04-30 Enanta Pharm Inc Macrocyclic proline derived hcv serine protease inhibitors
US8330139B2 (en) 2011-03-25 2012-12-11 Micron Technology, Inc. Multi-level memory cell
CH707029B1 (de) 2011-10-21 2015-03-13 Abbvie Inc Verfahren zur Behandlung von HCV, umfassend mindestens zwei direkt wirkende antivirale Wirkstoffe, Ribavirin, aber nicht Interferon.
EP2583680A3 (en) 2011-10-21 2013-06-12 Abbvie Inc. Mono (PSI-7977) or combination treatment of DAAs for use in treating HCV
PT2897611T (pt) * 2012-09-18 2019-11-27 Abbvie Inc Métodos para tratamento da hepatite c
RS56202B1 (sr) 2013-03-14 2017-11-30 Abbvie Inc Kombinacija dva antivirotika za lečenje hepatitisa c

Also Published As

Publication number Publication date
TWI686196B (zh) 2020-03-01
MX2015012538A (es) 2016-02-10
EP3213750B1 (en) 2020-08-12
JP2021130720A (ja) 2021-09-09
DK3213750T3 (da) 2020-10-19
RS56202B1 (sr) 2017-11-30
TW201834656A (zh) 2018-10-01
EP2968301B1 (en) 2017-04-19
MX362616B (es) 2019-01-28
IL240419B (en) 2019-03-31
EP3766495A1 (en) 2021-01-20
AU2014239563B2 (en) 2016-05-05
LT3213750T (lt) 2020-10-26
PL3213750T3 (pl) 2020-12-14
US20140275099A1 (en) 2014-09-18
LT2968301T (lt) 2017-05-25
PT2968301T (pt) 2017-07-17
CN108159393A (zh) 2018-06-15
KR20210013344A (ko) 2021-02-03
HK1244668A1 (zh) 2018-08-17
SG10201708306WA (en) 2017-11-29
EA201991174A1 (ru) 2020-01-31
TW201511759A (zh) 2015-04-01
AU2016202823A1 (en) 2016-05-19
BR112015023017B1 (pt) 2022-08-30
TWI642436B (zh) 2018-12-01
JP2016513695A (ja) 2016-05-16
CA2901810A1 (en) 2014-09-25
CN105073113B (zh) 2018-01-02
CY1123387T1 (el) 2021-12-31
EA201591702A1 (ru) 2016-09-30
JP2020037589A (ja) 2020-03-12
HUE033010T2 (en) 2017-11-28
CN105073113A (zh) 2015-11-18
AU2016202823B2 (en) 2017-11-23
PL2968301T3 (pl) 2017-09-29
SI3213750T1 (sl) 2020-11-30
EA033257B1 (ru) 2019-09-30
RS60881B1 (sr) 2020-11-30
PT3213750T (pt) 2020-10-19
JP2019048868A (ja) 2019-03-28
KR20150129032A (ko) 2015-11-18
JP6621902B2 (ja) 2019-12-18
CY1119025T1 (el) 2018-01-10
IL240419A0 (en) 2015-09-24
ES2624980T3 (es) 2017-07-18
MX2020005054A (es) 2020-08-20
CA2901810C (en) 2019-01-08
HUE052113T2 (hu) 2021-04-28
SI2968301T1 (sl) 2017-07-31
JP6441303B2 (ja) 2018-12-19
EP3213750A1 (en) 2017-09-06
EP2968301A1 (en) 2016-01-20
HRP20171036T1 (hr) 2017-10-06
AU2014239563A1 (en) 2015-08-27
DK2968301T3 (en) 2017-07-24
SG11201507364SA (en) 2015-10-29
NZ719137A (en) 2017-11-24
HRP20201575T1 (hr) 2020-12-11
NZ631155A (en) 2016-05-27
WO2014152514A1 (en) 2014-09-25
ES2824473T3 (es) 2021-05-12
HK1223817A1 (zh) 2017-08-11
KR102210935B1 (ko) 2021-02-02

Similar Documents

Publication Publication Date Title
BR112015023017A2 (pt) combinação de dois antivirais para o tratamento de hepatite c
BR112015020918A2 (pt) métodos para tratar o hcv
BR112016022976A8 (pt) métodos para o tratamento de hcv
BR112014005617A2 (pt) tratamento de combinação (por exemplo, com abt-072 ou abt -333) de daas para uso no tratamento de hcv
PH12018550201A1 (en) Hepatitis b antiviral agents
CR20150199A (es) Análogos de 2´-cloro nucleósido para infección por vhc
PH12014502603A1 (en) D-amino acid compounds for liver disease
PH12014502848A1 (en) Methods for treating hcv comprising at least two direct acting antiviral agent, ribavirin but not interferon
CL2021002747A1 (es) Agentes antivirales para la hepatitis b (solicitud divisional no. 487-2020)
BR112018000383A2 (pt) métodos para tratar hcv
MX2015017953A (es) Metodos para tratar el virus de hepatitis c.
MX2014009850A (es) Spiro [2.4] heptanos para aplicaciones relacionadas con el tratamiento de infecciones de flaviviridae.
MX2015004009A (es) Regimen de glicosidasa para el tratatamiento de enfermedades infecciosas.
MX2016012722A (es) Metodos para tratar el virus de la hepatitis c.
BR102017022849A8 (pt) Usos terapêuticos de agentes antivirais de ação direta para tratar ou prevenir uma infecção com genótipo 1 a 6 do vírus da hepatite c
MX2018001905A (es) Metodos para el tratamiento del virus de hepatitis c (vhc).
ES2572355A2 (es) Combinacion de aad para uso en el tratamiento del vhc
BR112015029121A2 (pt) solução protetora para previnir ou reduzir reperfusão do cérebro e corpo inteiro
CO7200247A2 (es) Compuestos d-aminoácidos para enfermedad hepática
NZ631789A (en) Combination of direct acting antiviral agents and ribavirin for treating hcv patients

Legal Events

Date Code Title Description
B07D Technical examination (opinion) related to article 229 of industrial property law [chapter 7.4 patent gazette]
B06F Objections, documents and/or translations needed after an examination request according [chapter 6.6 patent gazette]
B07G Grant request does not fulfill article 229-c lpi (prior consent of anvisa) [chapter 7.7 patent gazette]

Free format text: NOTIFICACAO DE DEVOLUCAO DO PEDIDO EM FUNCAO DA REVOGACAO DO ART. 229-C DA LEI NO 9.279, DE 1996, POR FORCA DA LEI NO 14.195, DE 2021

B06U Preliminary requirement: requests with searches performed by other patent offices: procedure suspended [chapter 6.21 patent gazette]
B06A Patent application procedure suspended [chapter 6.1 patent gazette]
B09A Decision: intention to grant [chapter 9.1 patent gazette]
B16A Patent or certificate of addition of invention granted [chapter 16.1 patent gazette]

Free format text: PRAZO DE VALIDADE: 20 (VINTE) ANOS CONTADOS A PARTIR DE 14/03/2014, OBSERVADAS AS CONDICOES LEGAIS